Expression of DNA topoisomerase IIα in oligodendroglioma

Anticancer Research

Volumn 22, Issue 2 B, 2002, Pages 1301-1304

  Bredel, Markus ^a   Gatterbauer, Brigitte ^a   Birner, Peter ^a   Haberler, Christine ^a   Ströbel, Thomas ^a   Budka, Herbert ^a   Rössler, Karl ^a   Hainfellner, Johannes A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cell proliferation; Etoposide (VP 16); Immunohistochemistry; MIB 1 proliferation index; Oligodendroglioma; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; MONOCLONAL ANTIBODY KI 67; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; MIDDLE AGED; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES;

EID: 0036323441     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Oligodendroglioma: Incidence and biological behavior in a defined population
2. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma
3. Oligodendrogliomas: The Mayo Clinic experience
4. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors
5. Aggressive oligodendroglioma: A chemosensitive tumor. Recent Results
6. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
7. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors
8. Current treatment of oligodendrogliomas
9. DNA topoisomerases
10. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas
11. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: Correlation with MIB1 expression and patient survival
12. High topoisomerase Ilalpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas
13. Antitopoisomerase drug action and resistance
14. Nonparametric estimation from incomplete observations
15. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas
16. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases
17. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma
18. Prognostic relevance of TP53 mutations, p53 protein, Ki67 index and conventional histological grading in oligodendrogliomas
19. Evaluation of malignant features in oligodendroglial tumors
20. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma
21. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
22. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas
23. Salvage chemotherapy for oligodendroglioma